Corinne Le Goff Biography and Net Worth

Chief Commercial Officer of Viatris

Corinne Le Goff is the Chief Commercial Officer of Viatris. She joined the company in April 2024.

Corinne is an accomplished biotechnology and pharmaceutical executive with more than 25 years of experience leading and building highly successful teams globally. She is a visionary and entrepreneurial leader with a strong scientific background and experience across multiple markets and therapeutic areas.

Prior to joining Viatris, Corinne was President and Chief Executive Officer of Imunon, a clinical-stage biotechnology company, where she led an organizational turnaround and rebranding effort. Prior Imunon, she served as Chief Commercial Officer at Moderna, with responsibility for building the commercial organization and key capabilities to ensure global access to the company’s COVID-19 vaccine. Corinne previously spent six years at Amgen, serving as President of the U.S. Business; Senior Vice President of Global Product Strategy & Commercial Innovation; and President of the Europe Region. She also held senior international roles at Roche, including President of Roche France and Head of Global Product Strategy, Neuroscience & Rare Diseases. Early in her career, she held various leadership positions at Merck, Sanofi and Pfizer.

Corinne earned a Pharm. D. from Paris Descartes University and a Master of Business Administration from La Sorbonne University, both in Paris.

She is a member of the Longboard Pharmaceuticals board of directors and has served previously on the boards of Euroapi, Acticor Biotech, CFAO Group and Amgen Foundation.

What is Corinne Le Goff's net worth?: The estimated net worth of Corinne Le Goff is at least $379.82 thousand as of September 11th, 2025. Ms. Le Goff owns 35,299 shares of Viatris stock worth more than $379,817 as of December 5th. This net worth estimate does not reflect any other assets that Ms. Le Goff may own. Learn More about Corinne Le Goff's net worth.
How do I contact Corinne Le Goff?: The corporate mailing address for Ms. Le Goff and other Viatris executives is 1000 MYLAN BOULEVARD, CANONSBURG PA, 15317. Viatris can also be reached via phone at (724) 514-1800 and via email at [email protected]. Learn More on Corinne Le Goff's contact information.
Has Corinne Le Goff been buying or selling shares of Viatris?: Corinne Le Goff has not been actively trading shares of Viatris during the last ninety days. Most recently, Goff Corinne Le sold 7,032 shares of the business's stock in a transaction on Thursday, September 11th. The shares were sold at an average price of $10.25, for a transaction totalling $72,078.00. Following the completion of the sale, the insider now directly owns 35,299 shares of the company's stock, valued at $361,814.75. Learn More on Corinne Le Goff's trading history.
Who are Viatris' active insiders?: Viatris' insider roster includes Paul Campbell (CAO and Corporate Controller), W. Cornwell (Director), Robert Coury (Chairman), Michael Goettler (CEO), James Kilts (Director), Corinne Le Goff (Chief Commercial Officer), JoElleng Lyons Dillon (Director), Rajiv Malik (Director), Brian Roman (Chief Legal Officer), Scott Smith (CEO), Menassie Taddese (insider), and Pauline van der Meer Morh (Director). Learn More on Viatris' active insiders.
Are insiders buying or selling shares of Viatris?: During the last twelve months, Viatris insiders bought shares 2 times. They purchased a total of 82,000 shares worth more than $756,180.00. During the last twelve months, insiders at the sold shares 1 times. They sold a total of 7,032 shares worth more than $72,078.00. The most recent insider tranaction occured on September, 11th when insider Goff Corinne Le sold 7,032 shares worth more than $72,078.00. Insiders at Viatris own 0.3% of the company. Learn More about insider trades at Viatris.
Information on this page was last updated on 9/11/2025.

Corinne Le Goff Insider Trading History at Viatris

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
9/11/2025	Sell	7,032	$10.25	$72,078.00	35,299

Corinne Le Goff Buying and Selling Activity at Viatris

Viatris Company Overview

Viatris Inc. operates as a healthcare company worldwide. The company operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. It offers prescription brand drugs, generic drugs, complex generic drugs, biosimilars, and active pharmaceutical ingredients (APIs). The company offers drugs in various therapeutic areas, including noncommunicable and infectious diseases; biosimilars in the areas of oncology, immunology, endocrinology, ophthalmology, and dermatology; and APIs for antibacterial, central nervous system agents, antihistamines/antiasthmatics, cardiovascular, antivirals, antidiabetics, antifungals, and proton pump inhibitor areas, as well as support services, such as diagnostic clinics, educational seminars, and digital tools to help patients better manage their health. It provides it medicines in the form of oral solid doses, injectables, complex dosage forms, and APIs to retail and pharmacy establishments, wholesalers and distributors, payers, insurers and governments, and institutions. The company distributes its products through pharmaceutical wholesalers/distributors, pharmaceutical retailers, institutional pharmacies, mail-order and e-commerce pharmacies, and specialty pharmacies. It sells its products under the Lyrica, Lipitor, Creon, Influvac, Wixela Inhub, EpiPen auto-injector, Fraxiparine, and Yupelri; Norvasc and Viagra; AMITIZA, Lipacreon, and Effexor; and Celebrex and ARV names, as well as glargine and SEMGLEE names. The company has collaboration and licensing agreements with Revance Therapeutics, Inc.; and Momenta Pharmaceuticals, Inc. Viatris Inc. was founded in 1961 and is headquartered in Canonsburg, Pennsylvania.

Today's Range

Now: $10.76

$10.67

$10.89

50 Day Range

MA: $10.35

$9.52

$11.20

2 Week Range

Now: $10.76

$6.85

$13.13

Volume

5,229,260 shs

Average Volume

8,288,455 shs

Market Capitalization

$12.39 billion

P/E Ratio

N/A

Dividend Yield

4.43%

Beta

0.84